New hope for rare metabolic disease patients: expanded access to triheptanoin

This program provides expanded access to triheptanoin for people with long-chain fatty acid oxidation disorders (LC-FAOD) who have few treatment options and cannot join a clinical trial. The goal is to help manage the disease by providing an alternative energy source for the body. It is not a cure, but aims to control the condition and improve quality of life.